# Portola Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/portola-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.portola.com
- Total disclosed funding: $286M
- Latest round: Series D (Nov 18, 2011)
- Investors on record: 21

## About

Portola Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and conditions, primarily through the creation of novel anticoagulants and effective treatment solutions.Founded in 2003 and headquartered in South San Francisco, US, Portola Pharmaceuticals specializes in the development of therapies targeting rare diseases. The company experienced significant growth, culminating in a successful IPO in May 2013, raising USD 122 mn by selling 8.4 million shares at USD 14.5 per share. Portola has executed a total of 9 deals since its inception.Portola Pharmaceuticals develops therapies for rare diseases, with a strong focus on anticoagulants. Their core product offerings aim to provide innovative treatment solutions for conditions related to thrombosis, thereby improving patient outcomes. The company’s therapies cater to healthcare providers and institutions across various markets, including North America and Europe, ensuring access to their products for patients with limited treatment options.For the most recent fiscal year in 2019, Portola Pharmaceuticals reported a revenue of USD 116.64 mn. The company's financial performance also indicated an EBITDA of USD -265.06 mn, reflecting the ongoing investment in research and development to expand its product offerings.Portola Pharmaceuticals aims to leverage the capital raised during its IPO to enhance its research and development efforts, focusing on new therapeutic products in the anticoagulant space. The company is exploring expansion into additional markets in Europe and Asia-Pacific by 2024. The recent funding will support the development of new drugs and facilitate entry into these new geographic regions, aiming to broaden its market presence and improve the lives of patients facing rare diseases.

## Funding rounds

- Series D, Nov 18, 2011, $89M — Temasek Holdings, East Capital Group
- Series C, Jul 8, 2008, $60M — Abingworth, Advanced Technology Ventures, Alta Partners, Frazier Healthcare Partners, Prospect Venture Partners, China Investment and Development Company, Brookside Capital Partners, Sutter Hill Ventures, Adage Capital Management, O-Bank, D. E. Shaw & Co, MPM BioImpact, Janus Henderson Investors, Teachers' Private Capital, Goldman Sachs Asset Management, BBT Capital Management, AllianceBernstein, Pac-Link BioVentures
- Series C, May 8, 2007, $70M — Abingworth, Advanced Technology Ventures, Alta Partners, Frazier Healthcare Partners, Prospect Venture Partners, T Rowe Price, China Investment and Development Company, Brookside Capital Partners, AllianceBernstein, Sutter Hill Ventures, O-Bank, MPM BioImpact, Teachers' Private Capital, Goldman Sachs Asset Management
- Series B, Dec 6, 2005, $46M — Abingworth, Advanced Technology Ventures, Alta Partners, Frazier Healthcare Partners, Prospect Venture Partners, Sutter Hill Ventures, MPM BioImpact
- Series A, Dec 8, 2003, $21M — Abingworth, Frazier Healthcare Partners, Prospect Venture Partners, Sutter Hill Ventures, MPM BioImpact

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series A, Series B, Series C
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A, Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series B, Series C
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- China Investment and Development Company (https://capitalatlas.ai/funds/china-investment-and-development-company) — Series C
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series C
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series C
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series C
- Teachers' Private Capital — Series C
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- Adage Capital Management — Series C
- D. E. Shaw & Co (https://capitalatlas.ai/funds/d-e-shaw-co) — Series C
- Janus Henderson Investors — Series C
- BBT Capital Management — Series C
- Pac-Link BioVentures — Series C
- Temasek Holdings — Series D
- East Capital Group (https://capitalatlas.ai/funds/east-capital-group) — Series D